

**PPARG Antibody (N-term)**  
**Purified Rabbit Polyclonal Antibody (Pab)**  
**Catalog # AP20705a**

**Specification**

---

**PPARG Antibody (N-term) - Product Information**

|                   |                        |
|-------------------|------------------------|
| Application       | WB,E                   |
| Primary Accession | <a href="#">P37231</a> |
| Reactivity        | Human, Mouse           |
| Host              | Rabbit                 |
| Clonality         | Polyclonal             |
| Isotype           | Rabbit IgG             |
| Calculated MW     | 57620                  |

**PPARG Antibody (N-term) - Additional Information**

**Gene ID** 5468

**Other Names**

Peroxisome proliferator-activated receptor gamma, PPAR-gamma, Nuclear receptor subfamily 1 group C member 3, PPARG, NR1C3

**Target/Specificity**

This PPARG antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 2-35 amino acids from the N-terminal region of human PPARG.

**Dilution**

WB~~1:1000

E~~Use at an assay dependent concentration.

**Format**

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

**Storage**

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

**Precautions**

PPARG Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.

**PPARG Antibody (N-term) - Protein Information**

**Name** PPARG

**Synonyms** NR1C3

**Function** Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated pro-inflammatory responses. Plays a role in the regulation of cardiovascular circadian rhythms by regulating the transcription of BMAL1 in the blood vessels (By similarity).

#### Cellular Location

Nucleus. Cytoplasm. Note=Redistributed from the nucleus to the cytosol through a MAP2K1/MEK1-dependent manner. NOCT enhances its nuclear translocation

#### Tissue Location


Highest expression in adipose tissue. Lower in skeletal muscle, spleen, heart and liver. Also detectable in placenta, lung and ovary.

### PPARG Antibody (N-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

### PPARG Antibody (N-term) - Images



Western blot analysis of lysates from human placenta and mouse heart tissue lysate (from left to right), using PPARG Antibody (N-term) (Cat. #AP20705a). AP20705a was diluted at 1:1000 at each lane. A goat anti-rabbit IgG H&L (HRP) at 1:5000 dilution was used as the secondary antibody. Lysates at 35ug per lane.

**PPARG Antibody (N-term) - Background**

Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses.

**PPARG Antibody (N-term) - References**

Mukherjee R.,et al.J. Biol. Chem. 272:8071-8076(1997).  
Elbrecht A.,et al.Biochem. Biophys. Res. Commun. 224:431-437(1996).  
Yanase T.,et al.Biochem. Biophys. Res. Commun. 233:320-324(1997).  
Greene M.E.,et al.Gene Expr. 4:281-299(1995).  
Greene M.E.,et al.Submitted (DEC-2001) to the EMBL/GenBank/DDBJ databases.

**PPARG Antibody (N-term) - Citations**

- [Qishen Yiqi Dripping Pill Protects Diabetic Nephropathy by Inhibiting the PI3K-AKT Signaling Pathways in Rats](#)
- [Pioglitazone increases VEGFR3 expression and promotes activation of M2 macrophages via the peroxisome proliferator-activated receptor  \$\gamma\$ .](#)